LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Search

Crinetics Pharmaceuticals Inc

Închisă

SectorSănătate

36.1 -0.47

Rezumat

Modificarea prețului

24h

Curent

Minim

35.66

Maxim

36.53

Indicatori cheie

By Trading Economics

Venit

7.3M

-123M

Vânzări

3.7M

3.9M

EPS

-1.29

Marjă de profit

-3,161.261

Angajați

594

EBITDA

20M

-122M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+142.16% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-855M

3.6B

Deschiderea anterioară

36.57

Închiderea anterioară

36.1

Sentimentul știrilor

By Acuity

50%

50%

164 / 349 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 mar. 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 mar. 2026, 23:36 UTC

Market Talk
Evenimente importante

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 mar. 2026, 23:35 UTC

Achiziții, Fuziuni, Preluări

Pernod Ricard: Confirms Discussions With Brown-Forman

26 mar. 2026, 23:29 UTC

Câștiguri

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 mar. 2026, 23:28 UTC

Câștiguri

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 mar. 2026, 23:28 UTC

Câștiguri

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 mar. 2026, 23:28 UTC

Câștiguri

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 mar. 2026, 23:27 UTC

Câștiguri

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 mar. 2026, 23:27 UTC

Câștiguri

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 mar. 2026, 23:08 UTC

Market Talk

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 mar. 2026, 23:04 UTC

Achiziții, Fuziuni, Preluări

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 mar. 2026, 23:04 UTC

Achiziții, Fuziuni, Preluări

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 mar. 2026, 23:04 UTC

Achiziții, Fuziuni, Preluări

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 mar. 2026, 23:04 UTC

Achiziții, Fuziuni, Preluări

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 mar. 2026, 23:04 UTC

Achiziții, Fuziuni, Preluări

Pernod in Deal Talks With Brown-Forman -- WSJ

26 mar. 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 mar. 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 mar. 2026, 22:26 UTC

Câștiguri

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 mar. 2026, 22:26 UTC

Câștiguri

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 mar. 2026, 22:26 UTC

Câștiguri

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 mar. 2026, 22:08 UTC

Câștiguri

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 mar. 2026, 22:08 UTC

Câștiguri

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 mar. 2026, 22:08 UTC

Câștiguri

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 mar. 2026, 22:07 UTC

Market Talk
Evenimente importante

Global Energy Roundup: Market Talk

26 mar. 2026, 22:07 UTC

Market Talk
Evenimente importante

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 mar. 2026, 22:00 UTC

Câștiguri

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 mar. 2026, 22:00 UTC

Câștiguri

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 mar. 2026, 22:00 UTC

Câștiguri

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 mar. 2026, 21:39 UTC

Achiziții, Fuziuni, Preluări

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 mar. 2026, 21:38 UTC

Achiziții, Fuziuni, Preluări

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Comparație

Modificare preț

Crinetics Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

142.16% sus

Prognoză pe 12 luni

Medie 88 USD  142.16%

Maxim 97 USD

Minim 67 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

12

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

30.39 / 33.46Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

164 / 349 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat